Research
Metabolic adaptation
Modern dual and triple agonists achieve surgical-level metabolic benefits, redefining diabetes and obesity care.
These agonists may offer new treatment options for diabetes and obesity.
StrongSupportsmedium confidence
Modern dual and triple agonists achieve surgical-level metabolic benefits, redefining diabetes and obesity care.
Why this rating
The claim is based on the effectiveness of dual and triple agonists.
Source
History of glucagon-like peptide-1 receptor agonists
Radwan Darwish et al. · Pharmacological Research · 2025
reviewCited 4×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →